{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:56:38Z","timestamp":1791093398164,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":4690,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1017\/s1041610211001487","type":"journal-article","created":{"date-parts":[[2011,8,11]],"date-time":"2011-08-11T14:12:54Z","timestamp":1313071974000},"page":"496-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Health management of older persons with chronically medicated psychotic disorders: the results of a survey in France"],"prefix":"10.1016","volume":"24","author":[{"given":"Christophe","family":"Arbus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Bougerol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Fremont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lancrenon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Camus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1017\/S1041610211001487_bb0010","first-page":"5","article-title":"Using antipsychotic agents in older patients","volume":"65","author":"for the Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610211001487_bb0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4088\/JCP.v64n0205","article-title":"A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia","volume":"64","author":"Brodaty","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610211001487_bb0020","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1038\/oby.2008.285","article-title":"Monitoring the obesity epidemic in France: the Obepi Surveys 1997\u20132006","volume":"16","author":"Charles","year":"2008","journal-title":"Obesity"},{"key":"10.1017\/S1041610211001487_bb0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-0179-2-14","article-title":"Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study","volume":"2","author":"De Hert","year":"2006","journal-title":"Clinical Practice and Epidemiology in Mental Health"},{"key":"10.1017\/S1041610211001487_bb0030","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/oxfordjournals.schbul.a033504","article-title":"Prevalence and correlates of diabetes in national schizophrenia samples","volume":"26","author":"Dixon","year":"2000","journal-title":"Schizophrenia Bulletin"},{"key":"10.1017\/S1041610211001487_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004850-200401000-00005","article-title":"Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients","volume":"19","author":"Drimer","year":"2004","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1017\/S1041610211001487_bb0040","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1176\/appi.ajp.158.9.1441","article-title":"Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging","volume":"158","author":"Friedman","year":"2001","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610211001487_bb0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1383\/psyt.2005.4.10.11","article-title":"The NICE guidelines for schizophrenia","volume":"4","author":"Gray","year":"2005","journal-title":"Psychiatry"},{"key":"10.1017\/S1041610211001487_bb0050","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0013-7006(04)95452-8","article-title":"Schizophr\u00e9nie, diab\u00e8te et antipsychotiques","volume":"30","author":"Gury","year":"2004","journal-title":"L'Enc\u00e9phale"},{"key":"10.1017\/S1041610211001487_bb0055","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1002\/1099-1166(200112)16:1+<::AID-GPS565>3.0.CO;2-V","article-title":"Cognitive impairment in elderly patients with schizophrenia: age related changes","volume":"16","author":"Harvey","year":"2001","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610211001487_bb0060","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1176\/ajp.155.8.1080","article-title":"Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites","volume":"155","author":"Harvey","year":"1998","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610211001487_bb0065","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","article-title":"Schizophrenia and increased risks of cardiovascular disease","volume":"150","author":"Hennekens","year":"2005","journal-title":"American Heart Journal"},{"key":"10.1017\/S1041610211001487_bb0070","unstructured":"hopital.fr (2010). La Psychiatrie. Available at: http:\/\/www.hopital.fr\/Hopitaux\/L-hopital-et-vous\/La-psychiatrie."},{"key":"10.1017\/S1041610211001487_bb0075","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/10673220500433247","article-title":"Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature","volume":"13","author":"Jeste","year":"2005","journal-title":"Harvard Review of Psychiatry"},{"key":"10.1017\/S1041610211001487_bb0080","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1176\/appi.ps.55.11.1250","article-title":"Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness","volume":"55","author":"Jones","year":"2004","journal-title":"Psychiatric Services"},{"key":"10.1017\/S1041610211001487_bb0085","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.diabet.2008.01.005","article-title":"Prevalence and treatment of diabetes in France: trends between 2000 and 2005","volume":"34","author":"Kusnik-Joinville","year":"2008","journal-title":"Diabetes and Metabolism"},{"key":"10.1017\/S1041610211001487_bb0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.amp.2005.11.006","article-title":"Comorbidit\u00e9s somatiques chez les patients souffrant de schizophrenie trait\u00e9e: recommandations actuelles","volume":"164","author":"Lefebvre","year":"2006","journal-title":"Annales Medico-psychologiques, Revue Psychiatrique"},{"key":"10.1017\/S1041610211001487_bb0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oxfordjournals.schbul.a007071","article-title":"The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003","volume":"30","author":"Lehman","year":"2004","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl. 2","key":"10.1017\/S1041610211001487_bb0100","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"for the American Psychiatric Association; Steering Committee on Practice Guidelines","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl. 1","key":"10.1017\/S1041610211001487_bb0105","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0013-7006(09)75531-9","article-title":"Schizophrenia and the elderly patient","volume":"35","author":"Limosin","year":"2009","journal-title":"L'Enc\u00e9phale"},{"key":"10.1017\/S1041610211001487_bb0110","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610211001487_bb0115","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2165\/00002512-200320150-00003","article-title":"Long-acting injectable antipsychotics in the elderly: guidelines for effective use","volume":"20","author":"Masand","year":"2003","journal-title":"Drugs and Aging"},{"key":"10.1017\/S1041610211001487_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1017\/S1041610211001487_bb0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2006.06.026","article-title":"Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline","volume":"86","author":"Nasrallah","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1017\/S1041610211001487_bb0130","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1176\/ajp.2006.163.12.2080","article-title":"Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia","volume":"163","author":"Rosenheck","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610211001487_bb0135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0013-7006(05)82412-1","article-title":"Prise de poids pharmaco-induite par les psychotropes et sa prise en charge: revue des donn\u00e9es de la litt\u00e9rature","volume":"31","author":"Ruetsch","year":"2005","journal-title":"L'Enc\u00e9phale"},{"key":"10.1017\/S1041610211001487_bb0140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.nmd.0000130135.78017.96","article-title":"Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services","volume":"192","author":"Sokal","year":"2004","journal-title":"Journal of Nervous Mental Disorders"},{"issue":"Suppl. 1","key":"10.1017\/S1041610211001487_bb0145","first-page":"S19","article-title":"The treatment of psychotic disorders in late life","volume":"42","author":"Thorpe","year":"1997","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1017\/S1041610211001487_bb0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2006.06.038","article-title":"Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: retrospective comparison of first generation and second generation antipsychotics","volume":"88","author":"White","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1017\/S1041610211001487_bb0155","series-title":"ICD-10: Mental and Behavioural Disorders","author":"WHO","year":"2007"},{"key":"10.1017\/S1041610211001487_bb0160","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0193-953X(02)00035-7","article-title":"Understanding the new and evolving profile of adverse drug effects in schizophrenia","volume":"26","author":"Wirshing","year":"2003","journal-title":"Psychiatric Clinics of North America"},{"key":"10.1017\/S1041610211001487_bb0165","first-page":"1269","article-title":"Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials","volume":"167","author":"Wooltorton","year":"2002","journal-title":"Canadian Medical Association Journal"},{"key":"10.1017\/S1041610211001487_bb0170","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1503\/cmaj.1040539","article-title":"Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials","volume":"170","author":"Wooltorton","year":"2004","journal-title":"Canadian Medical Association Journal"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224020660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224020660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1041610211001487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T14:11:19Z","timestamp":1735827079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610224020660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1041610224020660"],"URL":"https:\/\/doi.org\/10.1017\/s1041610211001487","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health management of older persons with chronically medicated psychotic disorders: the results of a survey in France","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1017\/S1041610211001487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Copyright \u00a9 International Psychogeriatric Association 2011. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}